🚀
Enjoy a 7-Day Free Trial Thru May 04, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Industrials
Waste Management
JanOne Inc (NAS:JAN)
News
JanOne Inc
NAS
:JAN (USA) Â
$ 5.10
+0.39 (+8.28%)
10:08 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 43.83M
Enterprise V:
$ 41.18M
Volume:
224.12K
Avg Vol (2M):
266.88K
Warning! GuruFocus detected 2 Severe warning signs with JAN.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
224.12K
Market Cap $:
43.83M
PE Ratio:
At Loss
Avg Vol (2M):
266.88K
Enterprise Value $:
41.18M
PB Ratio:
0
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
JanOne Inc (NAS:JAN) Stock News, Headlines & Updates
JanOne Inc Stock News from GuruFocus
Total 62
1
2
Mar 15, 2024
JanOne Regains Compliance with Nasdaq's Listing Requirements
PRNewswire
•
9:00am
Sep 21, 2023
JanOne to Present at the Dawson James 8th Annual Investment Conference
PRNewswire
•
11:00am
Aug 31, 2023
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference
PRNewswire
•
1:00pm
Aug 29, 2023
JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain
PRNewswire
•
1:00pm
Aug 25, 2023
JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting
PRNewswire
•
2:00pm
Aug 22, 2023
JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules
PRNewswire
•
5:00pm
Aug 19, 2023
JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules
PRNewswire
•
7:00pm
Aug 18, 2023
JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting
PRNewswire
•
12:00pm
Jun 28, 2023
JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain
PRNewswire
•
8:00am
Feb 16, 2022
Birch Run Capital Advisors, LP Buys JanOne Inc, Sells Par Pacific Holdings Inc, , Newmark Group Inc
GuruFocusNews
•
5:38pm
Jul 22, 2021
JanOne Selects CPC Clinical Research as Trial Manager for Phase 2b Study of JAN101 for Peripheral Artery Disease Patients
PRNewswire
•
9:01am
Jun 23, 2021
JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites
PRNewswire
•
10:00am
Jun 22, 2021
JanOne Selects Regulatory Partner for Phase 2b Trial as Investigational Plan is Prepared for FDA Filing
PRNewswire
•
9:01am
Jun 15, 2021
JanOne Appoints Internationally Renowned Expert on Addiction Nicholas Goeders, Ph.D. to Scientific Advisory Board
PRNewswire
•
10:00am
Jun 10, 2021
JanOne Engages DC Consulting LLC for Government and Private Sector Initiatives
PRNewswire
•
10:00am
Jun 08, 2021
JanOne Advances Toward Initiation of Phase 2b Peripheral Artery Disease (PAD) Trial for Lead Product Candidate JAN101
PRNewswire
•
9:00am
Feb 25, 2021
JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million
PRNewswire
•
11:05am
Feb 02, 2021
JanOne Announces Closing of $6.0 Million Common Stock Offering
PRNewswire
•
11:03am
Jan 29, 2021
JanOne Prices $6.0 Million Common Stock Offering
PRNewswire
•
11:03am
Sep 24, 2020
JanOne Successfully Begins Production of JAN101 cGMP Batch for Phase 2b Peripheral Artery Disease (PAD) Trial and Potential Covid-19 Study
PRNewswire
•
11:03am
Sep 22, 2020
JanOne Issues September 2020 Shareholder Letter Updating Investors on Recent Pharma Asset Potential for Peripheral Artery Disease
PRNewswire
•
11:02am
Sep 16, 2020
JanOne Announces Strategic Plan to Divest its Legacy Businesses
PRNewswire
•
3:01pm
Sep 03, 2020
JanOne confirms stability data of JAN101 development batch and prepares for commercial GMP production to support the upcoming PAD and potential Covid-19 clinical trials
PRNewswire
•
11:02am
Aug 28, 2020
JanOne Selects Partner for Bottling and Labeling of JAN101 for Peripheral Artery Disease and Potential Covid-19 Clinical Trials
PRNewswire
•
3:00pm
Aug 26, 2020
JanOne Advances its Potential Peripheral Artery Disease and Covid-19 Vascular Inflammation Treatment Towards Trial Readiness
PRNewswire
•
11:02am
Aug 21, 2020
JanOne to Host Telebriefing to Discuss Drug Candidate JAN101 for Treatment of Peripheral Artery Disease (PAD) and Potential Applications for COVID-19 Vascular Complications
PRNewswire
•
11:01am
Aug 19, 2020
JanOne to Present at The LD 500 Virtual Conference
PRNewswire
•
3:00pm
Aug 06, 2020
JanOne Engages CATO SMS, a World-Leading CRO, to Assist in the Development of JAN101 to Treat COVID-19 Vascular Complications
PRNewswire
•
3:00pm
Aug 04, 2020
JanOne Changes Internal Drug Candidate Name from TV1001SR to JAN101
PRNewswire
•
11:03am
Jul 30, 2020
JanOne bolsters its scientific advisory board with two leaders in the medical field for vascular regeneration and interventional pain
PRNewswire
•
11:02am
Jul 21, 2020
JanOne Receives FDA Authorization for Transfer of Investigational New Drug (IND) Application for its Sodium Nitrite Tablets
PRNewswire
•
11:02am
Jul 08, 2020
Dr. Rakesh Patel, internationally recognized scientist in nitric oxide and redox biology, and Dr. Timothy Ness, a pain mechanisms and medication expert, join JanOne's Scientific Advisory Board
PRNewswire
•
11:01am
Jun 30, 2020
One of the nation's most renowned pain experts, Dr. Edgar Ross, joins JanOne's Scientific Advisory Board
PRNewswire
•
11:02am
Jun 25, 2020
JanOne taps distinguished chemist Dr. Doug Flanagan as chief formulation advisor
PRNewswire
•
3:01pm
Jun 18, 2020
JanOne Launches Strategic Alternatives Process for Legacy Businesses
PRNewswire
•
11:02am
Feb 06, 2020
JanOne strikes agreement with CoreRx, a leading cGMP contract manufacturer, for Phase 2b clinical formulation and development
PRNewswire
•
11:02am
Jan 28, 2020
Amol Soin, MD, One Of The Nation's Leading Pain Experts, Named As JanOne's Chief Medical Officer
PRNewswire
•
11:04am
Jan 23, 2020
JanOne Scientific Advisory Board Chair and Leading Pain Expert Featured on ABC-7 WJLA America This Week
PRNewswire
•
11:01am
Jan 16, 2020
Leading Cardiovascular Researcher And PAD Treatment Pioneer, Dr. Christopher Kevil, To Chair JanOne Scientific Advisory Board
PRNewswire
•
11:02am
Dec 03, 2019
JanOne Names Tony Giordano, Ph.D., as Chief Scientific Officer
PRNewswire
•
11:01am
Total 62
1
2
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news